435 related articles for article (PubMed ID: 24410566)
1. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease.
Lin CH; Huang YJ; Lin CJ; Lane HY; Tsai GE
Curr Pharm Des; 2014; 20(32):5169-79. PubMed ID: 24410566
[TBL] [Abstract][Full Text] [Related]
2. Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.
Cheng YJ; Lin CH; Lane HY
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668976
[TBL] [Abstract][Full Text] [Related]
3. Dysfunctional synapse in Alzheimer's disease - A focus on NMDA receptors.
Mota SI; Ferreira IL; Rego AC
Neuropharmacology; 2014 Jan; 76 Pt A():16-26. PubMed ID: 23973316
[TBL] [Abstract][Full Text] [Related]
4. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
[TBL] [Abstract][Full Text] [Related]
5. Impairment of Glycolysis-Derived l-Serine Production in Astrocytes Contributes to Cognitive Deficits in Alzheimer's Disease.
Le Douce J; Maugard M; Veran J; Matos M; Jégo P; Vigneron PA; Faivre E; Toussay X; Vandenberghe M; Balbastre Y; Piquet J; Guiot E; Tran NT; Taverna M; Marinesco S; Koyanagi A; Furuya S; Gaudin-Guérif M; Goutal S; Ghettas A; Pruvost A; Bemelmans AP; Gaillard MC; Cambon K; Stimmer L; Sazdovitch V; Duyckaerts C; Knott G; Hérard AS; Delzescaux T; Hantraye P; Brouillet E; Cauli B; Oliet SHR; Panatier A; Bonvento G
Cell Metab; 2020 Mar; 31(3):503-517.e8. PubMed ID: 32130882
[TBL] [Abstract][Full Text] [Related]
6. Time-dependent effect of oligomeric amyloid-β (1-42)-induced hippocampal neurodegeneration in rat model of Alzheimer's disease.
Karthick C; Nithiyanandan S; Essa MM; Guillemin GJ; Jayachandran SK; Anusuyadevi M
Neurol Res; 2019 Feb; 41(2):139-150. PubMed ID: 30453864
[TBL] [Abstract][Full Text] [Related]
7. Central role for NMDA receptors in redox mediated impairment of synaptic function during aging and Alzheimer's disease.
Foster TC; Kyritsopoulos C; Kumar A
Behav Brain Res; 2017 Mar; 322(Pt B):223-232. PubMed ID: 27180169
[TBL] [Abstract][Full Text] [Related]
8. Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures.
Ferreira IL; Bajouco LM; Mota SI; Auberson YP; Oliveira CR; Rego AC
Cell Calcium; 2012 Feb; 51(2):95-106. PubMed ID: 22177709
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
[TBL] [Abstract][Full Text] [Related]
10. NMDA neurotransmission as a critical mediator of borderline personality disorder.
Grosjean B; Tsai GE
J Psychiatry Neurosci; 2007 Mar; 32(2):103-15. PubMed ID: 17353939
[TBL] [Abstract][Full Text] [Related]
11. Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.
Forsyth JK; Bachman P; Mathalon DH; Roach BJ; Ye E; Asarnow RF
Schizophr Bull; 2017 Sep; 43(5):1123-1133. PubMed ID: 28338977
[TBL] [Abstract][Full Text] [Related]
12. NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.
Huang YJ; Lin CH; Lane HY; Tsai GE
Curr Neuropharmacol; 2012 Sep; 10(3):272-85. PubMed ID: 23450042
[TBL] [Abstract][Full Text] [Related]
13. Role of Glutamate and NMDA Receptors in Alzheimer's Disease.
Wang R; Reddy PH
J Alzheimers Dis; 2017; 57(4):1041-1048. PubMed ID: 27662322
[TBL] [Abstract][Full Text] [Related]
14. Deficit of NMDA receptor activation in CA1 hippocampal area of aged rats is rescued by D-cycloserine.
Billard JM; Rouaud E
Eur J Neurosci; 2007 Apr; 25(8):2260-8. PubMed ID: 17445224
[TBL] [Abstract][Full Text] [Related]
15. Rodent models of memory dysfunction in Alzheimer's disease and normal aging: moving beyond the cholinergic hypothesis.
Ingram DK; Spangler EL; Iijima S; Ikari H; Kuo H; Greig NH; London ED
Life Sci; 1994; 55(25-26):2037-49. PubMed ID: 7997063
[TBL] [Abstract][Full Text] [Related]
16. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the NMDA receptor-mediated synaptic response by acetylcholinesterase inhibitors and its impairment in an animal model of Alzheimer's disease.
Chen G; Chen P; Tan H; Ma D; Dou F; Feng J; Yan Z
Neurobiol Aging; 2008 Dec; 29(12):1795-804. PubMed ID: 17555845
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IL-1β Signaling Normalizes NMDA-Dependent Neurotransmission and Reduces Seizure Susceptibility in a Mouse Model of Creutzfeldt-Jakob Disease.
Bertani I; Iori V; Trusel M; Maroso M; Foray C; Mantovani S; Tonini R; Vezzani A; Chiesa R
J Neurosci; 2017 Oct; 37(43):10278-10289. PubMed ID: 28924012
[TBL] [Abstract][Full Text] [Related]
19. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
20. Modulating the Balance of Synaptic and Extrasynaptic NMDA Receptors Shows Positive Effects against Amyloid-β-Induced Neurotoxicity.
Huang Y; Shen W; Su J; Cheng B; Li D; Liu G; Zhou WX; Zhang YX
J Alzheimers Dis; 2017; 57(3):885-897. PubMed ID: 28269783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
